Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment

Inclusion Criteria: * Presence of subfoveal CNV due to AMD, less than 9 disc areas in extent * Vision 20/40 to 20/800 Snellen equivalent * Age \> 50 years * Ability to provide written informed consent and comply with study assessments for the full duration of the study Exclusion Criteria: * Intraocular surgery or injection within 30 days prior to enrollment in the study eye * Intravitreal triamcinolone within the past 6 months in the study eye * History of prior PDT treatment in the study eye * History of argon laser treatment of subfoveal CNV in the study eye * Other vision-limiting disease (e.g. advanced glaucoma, prior vascular occlusion, dense amblyopia) in the study eye * Clinically significant intraocular inflammation in the study eye * No light perception in the fellow eye * Anterior segment opacity preventing adequate visualization of fundus for FA or OCT * Are currently participating in another clinical trial * Women of childbearing potential not using adequate contraception, as well as women who are breastfeeding * Known sensitivity to study drug(s) or class of study drug(s) * Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study * Use of any other investigational agent in the last 30 days